Header Logo

Connection

JOSEPH JANKOVIC to Levodopa

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Levodopa.
JOSEPH JANKOVIC
Connection Strength
5.423
Levodopa
  1. Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis. Mov Disord Clin Pract. 2024 Oct; 11(10):1195-1202.
    View in: PubMed
    Score: 0.894
  2. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
    View in: PubMed
    Score: 0.502
  3. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007; 21(8):677-92.
    View in: PubMed
    Score: 0.263
  4. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
    View in: PubMed
    Score: 0.229
  5. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005; 20 Suppl 11:S3-10.
    View in: PubMed
    Score: 0.229
  6. Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022 06; 22(6):489-498.
    View in: PubMed
    Score: 0.192
  7. Levodopa strengths and weaknesses. Neurology. 2002 Feb 26; 58(4 Suppl 1):S19-32.
    View in: PubMed
    Score: 0.188
  8. Parkinson's disease. A half century of progress. Neurology. 2001 Nov; 57(10 Suppl 3):S1-3.
    View in: PubMed
    Score: 0.184
  9. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):252-61.
    View in: PubMed
    Score: 0.170
  10. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000; 55(12 Suppl 6):S2-6.
    View in: PubMed
    Score: 0.162
  11. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
    View in: PubMed
    Score: 0.162
  12. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
    View in: PubMed
    Score: 0.157
  13. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
    View in: PubMed
    Score: 0.156
  14. Diagnosis and Management of Parkinson's Disease. Semin Neurol. 2017 04; 37(2):118-126.
    View in: PubMed
    Score: 0.135
  15. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.132
  16. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016; 17(7):895-909.
    View in: PubMed
    Score: 0.124
  17. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
    View in: PubMed
    Score: 0.112
  18. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):142-8.
    View in: PubMed
    Score: 0.104
  19. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014 Jan; 17(1):104-6.
    View in: PubMed
    Score: 0.102
  20. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
    View in: PubMed
    Score: 0.084
  21. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
    View in: PubMed
    Score: 0.077
  22. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
    View in: PubMed
    Score: 0.076
  23. Parkinson's disease: recent advances in therapy. South Med J. 1988 Aug; 81(8):1021-7.
    View in: PubMed
    Score: 0.073
  24. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006 Aug; 21(8):1252-4.
    View in: PubMed
    Score: 0.064
  25. Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006 Aug; 6(8):1181-97.
    View in: PubMed
    Score: 0.064
  26. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul; 73(4):682-9.
    View in: PubMed
    Score: 0.063
  27. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
    View in: PubMed
    Score: 0.055
  28. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004 Jan 27; 62(2):343; author reply 343-4.
    View in: PubMed
    Score: 0.054
  29. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
    View in: PubMed
    Score: 0.053
  30. Association of clinical outcomes and connectivity in awake versus asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2023 04 01; 138(4):1016-1027.
    View in: PubMed
    Score: 0.048
  31. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.047
  32. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001 Oct; 8(2):109-21.
    View in: PubMed
    Score: 0.046
  33. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.044
  34. Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001 Mar; 114(3):227-34.
    View in: PubMed
    Score: 0.044
  35. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000 Oct; 57(10):1464-9.
    View in: PubMed
    Score: 0.043
  36. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
    View in: PubMed
    Score: 0.038
  37. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999; 64(15):1275-85.
    View in: PubMed
    Score: 0.038
  38. Dystonia. Nat Rev Dis Primers. 2018 09 20; 4(1):25.
    View in: PubMed
    Score: 0.037
  39. Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997 Aug; 54(8):1026-9.
    View in: PubMed
    Score: 0.034
  40. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997; 58(4):153-62.
    View in: PubMed
    Score: 0.033
  41. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993 Oct; 8(4):525-32.
    View in: PubMed
    Score: 0.026
  42. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May; 23(5):466-9.
    View in: PubMed
    Score: 0.018
  43. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.018
  44. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
    View in: PubMed
    Score: 0.018
  45. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.012
  46. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000 Feb; 101(2):79-84.
    View in: PubMed
    Score: 0.010
  47. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999 Feb; 56(2):194-200.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.